Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R. Delord JP, et al. Among authors: mery mignard d. Br J Cancer. 2005 Mar 14;92(5):820-6. doi: 10.1038/sj.bjc.6602354. Br J Cancer. 2005. PMID: 15756252 Free PMC article. Clinical Trial.
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW. Soria JC, et al. Among authors: mery mignard d. Eur J Cancer. 2013 May;49(8):1799-807. doi: 10.1016/j.ejca.2013.01.003. Epub 2013 Feb 26. Eur J Cancer. 2013. PMID: 23485230 Clinical Trial.
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P. Ducreux M, et al. J Clin Oncol. 1999 Sep;17(9):2901-8. doi: 10.1200/JCO.1999.17.9.2901. J Clin Oncol. 1999. PMID: 10561369
Circadian rhythm of irinotecan tolerability in mice.
Filipski E, Lemaigre G, Liu XH, Méry-Mignard D, Mahjoubi M, Lévi F. Filipski E, et al. Among authors: mery mignard d. Chronobiol Int. 2004 Jul;21(4-5):613-30. doi: 10.1081/cbi-120040183. Chronobiol Int. 2004. PMID: 15470958
18 results